Pricing

There’s a stampede to relate prices to broader health benefits, but little consensus on how to do so, writes Jill Wechsler.

Even though pharma's “dark days” are fading away, the chill of the last few months will not soon be forgotten, writes Tom Norton.

The importance of betting on outcomes, not simply risk sharing, when implementing pharma-payer arrangements. .

Pharm Exec talks value-based healthcare with Professor Bengt Jönsson of the Stockholm School of Economics.

How a broader “value” understanding can benefit brand teams.

What are the chances that Rx price controls will actually take hold in the U.S. in the near future? Tom Norton believes the answer to that question can summed up in one word: California.

Scale has its limits, as the nation’s two largest pharmacy benefit managers (PBM), Express Scripts and CVS Caremark, are discovering. Stephen Littlejohn reports.

Peter Houston was surprised to find himself discussing Turing Pharmaceutical’s Daraprim in the offices of ClassicRock magazine last week. What’s even more surprising was impact the price hike on the toxoplasmosis treatment was having on a punk record label.

Following the backlash over the Turing Pharma drug price rise, the healthcare industry can not afford to ignore the signals and must carefully consider what to do next, writes Meg Alexander.

A slightly different take on this Turing Pharmaceuticals/Martin Shkreli business?

Kaiser’s August healthcare poll results should put all on high alert given public sentiment and the rhetoric of the political season. Ed Schoonveld sounds the alarm and offers four initiatives to stall the surge towards government intercession on escalating prices.

The clocks are ticking for Express Scripts, writes Stephen E. Littlejohn. Having achieved formidable “size and scale,” how will the nation’s largest pharmacy benefit manager synchronize with value-based health care?

BIG DATA IS BIG-it’s the one trend in healthcare that demands to be described in superlatives.

What will the ASCO Value Framework mean for the industry? Ram Subramanian from Simon-Kucher & Partners gives six items to think about.

Learnings gleaned from our annual EAB meeting, hosted this year by Dr. David Nash, Dean of the Thomas Jefferson University School of Population Health.

Making sense of the new cost-containment model and value-for-money conundrums like those in the HCV space.

Recent developments in the pharmaceutical industry give the strong impression that both payers and industry are struggling to understand what represents “value” to customers, writes Ed Schoonveld.

Pharm Exec speaks with IMS Health's John Daly and John Moran about new ways IDNs are impacting the healthcare decision landscape and the advantages of what they call “smart targeting”.

In the shift from volume to value as the underlying driver in health care, pharma has only scratched the surface of possibility for new and non-traditional arrangements with a broader variety of partners with healthcare interests, writes Cliff Kalb.

"Global free-riding" is the perception that the U.S. is subsidizing drugs for the rest of the world due to its high drug prices compared to other countries in the world.

CMS's Part B data release has increased transparency but has also resulted in potentially misplaced scrutiny of high-billing doctors. Ben Scher, Kathleen Twigg, and Andrew Huson take a closer look.

A global life-cycle management strategy should be baked into a drug's initial price at launch, write Alice Swearingen and Patrick Homer.

Why Real World Evidence (RWE) is here to stay, and what you need to do to integrate it into your business strategy as painlessly as possible.

Data has become as important as the drug in driving success in healthcare.

In the rush to collect as much patient data as possible, are we sacrificing quality for quantity? Ben Comer reports.

In establishing the value of new medicines, old-way theory is yielding to real-world practice - but there are risks in being 'of the moment'.

Diagnostics can bost the efficacy of drug treatments, but delivering the promise depends on a predictible pathway to reimbursement.

Do drug co-pay cards lead to skyrocketing healthcare inflation or provide patients access to valuable medicines?

The strict regulatory divide between market authorization and price reimbursement iscrumbling in the US. Is industry prepared to adapt or challenge?

The Deficit Reduction Act was designed to save the government money on Medicaid. But it also has the potential to change the very way pharma companies conduct business-if they can just figure it out.